Earlier this week, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it has initiated a phase II pivotal study that will evaluate the safety and efficacy of AP26113 in locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer’s (PFE – Analyst Report) Xalkori (crizotinib). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -1.16% in last session and finished the day at $7.67. Traded volume was 9.95million shares in the last session and the average volume of the stock remained 21.42million shares. The beta of the stock remained 1.42. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) insider ownership is 1.70%.
Shares of Insmed Incorporated (NASDAQ:INSM) declined sharply Wednesday after the biotech said its Arikayce drug candidate fell short of its primary goal in Phase II testing of the prospective treatment for lung diseases. Insmed Incorporated (NASDAQ:INSM) dropped -13.09 percent to $15.90 Wednesday on volume of 7.81million shares. The intra-day range of the stock was $15.55 to $17.38. Insmed Incorporated (NASDAQ:INSM) has a market capitalization of $624.49million.
Brinson Patrick initiated coverage on shares of Rexahn Pharmaceuticals Inc (NYSE:RNN) in a research note released on Monday morning, TheFlyOnTheWall.com reports. The firm issued an outperform rating on the stock. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)’s stock on Mar 26, 2014 reported a decrease of -8.13% to the closing price of $1.13. Its fifty two weeks range is $0.28 -$1.85. The total market capitalization recorded $199.48million. The overall volume in the last trading session was 8.65million shares. In its share capital, RNN has 130.47million outstanding shares.
Inovio Pharmaceuticals Inc. (NYSEMKT:INO) announced that it was recognized with three industry awards at the World Vaccine Congress, being held this week in Washington, D.C. The Vaccine Industry Excellence (ViE) Awards recognize outstanding vaccine advancements and achievements of therapeutic and preventive vaccine developers across the global industry as judged by a panel of global biotech industry stakeholders. On Wednesday, shares of Inovio Pharmaceuticals Inc (NYSEMKT:INO) close the day at $3.23. Company return on investment (ROI) is -37.10% and its monthly performance is recorded as -9.27%. Inovio Pharmaceuticals Inc (NYSEMKT:INO) quarterly revenue growth is 34.58%.